Phase II study of axitinib in sorafenib-refractory metastatic ... - UroToday PDF Print
UroToday... 2, and 3 in patients with metastatic renal cell carcinoma (mRCC) refractory to prior therapies that included, but were not limited to, sorafenib.

... read more

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.